Emergent BioSolutions | EBS - Beban Penjualan Dan Administrasi





Beban Penjualan Dan Administrasi Perubahan Tanggal
Acadia Pharmaceuticals USD 160.79M 14.06M 2026-03
Akebia Therapeutics USD 23.53M 3.19M 2025-12
ALKERMES USD 264.59M 77.4M 2026-03
Alnylam Pharmaceuticals USD 282.51M 2.55M 2026-03
Amarin USD 18.97M 1.03M 2025-12
ANI Pharmaceuticals USD 73.66M 9.14M 2026-03
BioMarin Pharmaceutical USD 258.28M 63.92M 2026-03
Coherus Biosciences USD 15M 6.26M 2025-12
Emergent BioSolutions USD 182.8M 82.3M 2023-06
Exelixis USD 139.6M 16.58M 2026-03
Glaxosmithkline GBP 3.56B 650.29M 2025-12
Heron Therapeutics USD 23.74M 605K 2025-12
Ionis Pharmaceuticals USD 151M 21M 2026-03
Ironwood Pharmaceuticals USD 33.33M 2.78M 2024-12
Lexicon Pharmaceuticals USD 3.98M 195K 2025-12
Merck USD 2.67B 180M 2026-03
Moderna USD 173M 135M 2026-03
Myriad Genetics USD 122.3M 6.7M 2025-12
Nektar Therapeutics USD 10.17M 10.17M 2025-12
Neurocrine Biosciences USD 318.5M 16.7M 2026-03
Pacira USD 83.88M 7.99M 2026-03
Pfizer USD 2.92B 1.16B 2026-03
PTC Therapeutics USD 73.89M 13.31M 2026-03
Sanofi EUR 2.33B 419M 2026-03
Sarepta Therapeutics USD 54.03M 51.35M 2026-03
United Therapeutics USD 156.6M 34M 2026-03
Vanda Pharmaceuticals USD 39.28M 1.71M 2024-12
Xoma USD 11M 2.54M 2024-06